Previous Antiretroviral Exposure Does Not Impede PI-Based Treatment in Pregnant Women

Response to protease inhibitor–based treatment regimens was similar between pregnant women who received antiretrovirals for PMTCT of HIV during a prior pregnancy and those who were antiretroviral-naive.

Women who receive single-dose nevirapine for prevention of mother-to-child transmission (PMTCT) of HIV have an increased risk for virologic failure on later treatment regimens containing nonnucleoside reverse transcriptase inhibitors (JW AIDS Clin Care Oct 18 2010). In many developed countries, regimens other than single-dose nevirapine are now used for PMTCT, but little is known about how exposure to these regimens might influence treatment response during a subsequent pregnancy. Data from the French Perinatal Cohort provide some insight.

Investigators analyzed data from 1007 HIV-infected women who initiated protease inhibitor (PI)-based antiretroviral therapy (ART) during a pregnancy between 2005 and 2009. Of these women, 788 were antiretr…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Previous Antiretroviral Exposure Does Not Impede PI-Based Treatment in Pregnant Women

Topics

Reviewing Author